We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.66%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$167M
AUM Growth
-$1.27M
Cap. Flow
+$3.86M
Cap. Flow %
2.31%
Top 10 Hldgs %
72.22%
Holding
63
New
9
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$944K
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$591K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$506K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$428K
5
ELUT icon
Elutia
ELUT
+$346K

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$461K
2
NKTR icon
Nektar Therapeutics
NKTR
+$369K
3
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$238K
4
BLUE
bluebird bio
BLUE
+$46K
5
OVV icon
Ovintiv
OVV
+$4.03K

Sector Composition

Rank Sector Weight
1 Healthcare 96.67%
2 Energy 1.69%
3 Consumer Staples 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$517M
$1.16M 0.69%
15,000
– –
ETRN
27
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.13M 0.68%
133,050
– –
CORT icon
28
Corcept Therapeutics
CORT
$9.89B
$1.1M 0.66%
50,000
– –
OVV icon
29
Ovintiv
OVV
$16.5B
$1.08M 0.64%
34,200
-150
-0.4% -$4.03K
SLNO
30
DELISTED
Soleno Therapeutics
SLNO
$1M 0.6%
58,460
– –
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$971K 0.58%
10,000
– –
BIOR
32
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$964K 0.58%
1,080
– –
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$958K 0.57%
40,000
– –
PGNY icon
34
Progyny
PGNY
$2.51B
$885K 0.53%
15,000
– –
CFRX
35
DELISTED
ContraFect Corporation
CFRX
$880K 0.53%
2,500
– –
GTHX
36
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$878K 0.53%
40,000
– –
TBIO
37
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$826K 0.49%
30,000
– –
NARI
38
DELISTED
Inari Medical, Inc. Common Stock
NARI
$653K 0.39%
7,000
– –
TPTX
39
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$624K 0.37%
+8,000
New +$591K
PXD
40
DELISTED
Pioneer Natural Resource Co.
PXD
$618K 0.37%
3,800
– –
TGTX icon
41
TG Therapeutics
TGTX
$8.39B
$582K 0.35%
15,000
– –
AWH
42
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$579K 0.35%
6,874
– –
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$506K 0.3%
8,000
– –
STOK icon
44
Stoke Therapeutics
STOK
$1.74B
$505K 0.3%
15,000
– –
PTGX icon
45
Protagonist Therapeutics
PTGX
$8.89B
$449K 0.27%
10,000
– –
ZNTL icon
46
Zentalis Pharmaceuticals
ZNTL
$372M
$426K 0.25%
+8,000
New +$428K
XNCR icon
47
Xencor
XNCR
$1.4B
$424K 0.25%
12,300
– –
LSF icon
48
Laird Superfood
LSF
$47.9M
$418K 0.25%
14,000
– –
CCXI
49
DELISTED
ChemoCentryx, Inc.
CCXI
$402K 0.24%
30,000
– –
AKBA icon
50
Akebia Therapeutics
AKBA
$341M
$379K 0.23%
+100,000
New +$337K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Birchview Capital held 63 positions worth $167M, down 0.75% from $168M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Birchview Capital's Q2 2021 filing shows 9 new, 5 increased, 4 reduced and 1 closed positions. Its largest new stake was Prothena Corp: 30,247 shares worth $1.55M. The largest sale was Cullinan Oncology, an estimated $461K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2021 buy was Prothena Corp: 30,247 shares worth $1.55M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q2 2021, an estimated $506K increase.
  • Birchview Capital's biggest Q2 2021 reduction was Cullinan Oncology, cutting an estimated $461K.
  • Birchview Capital fully exited Yield10 Bioscience, Inc. Common Stock in Q2 2021, selling an estimated $238K.
  • Birchview Capital's ten largest holdings make up 72% of its $167M portfolio in Q2 2021.
  • Birchview Capital opened 9 new positions and closed 1 in Q2 2021.
  • Birchview Capital's portfolio value fell 0.75% quarter-over-quarter to $167M.

Based on Birchview Capital's 13F filing for Q2 2021, filed 10 Aug 2021.